| GTO ID | GTC2445 |
| Trial ID | NCT04536922 |
| Disease | Anal Squamous Cell Carcinoma |
| Altered gene | Neoantigen |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Neoantigen TCR-T cells |
| Co-treatment | Pembrolizumab |
| HLA | unspecified |
| Phase | Phase2 |
| Recruitment status | Withdrawn |
| Title | Single Patient Protocol: A Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab |
| Year | 2020 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 10000163|000163-C |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||